Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses

被引:2
|
作者
van der Straten, Karlijn [1 ,2 ]
Guerra, Denise [1 ,2 ]
Kerster, Gius [1 ,2 ]
Claireaux, Mathieu [1 ,2 ]
Grobben, Marloes [1 ,2 ]
Schriek, Angela I. [1 ,2 ]
Boyd, Anders [3 ,4 ]
van Rijswijk, Jacqueline [1 ,2 ]
Tejjani, Khadija [1 ,2 ]
Eggink, Dirk [1 ,2 ,5 ]
Beaumont, Tim [1 ,2 ]
de Taeye, Steven W. [1 ,2 ]
de Bree, Godelieve J. [2 ,6 ]
Sanders, Rogier W. [1 ,2 ,7 ]
van Gils, Marit J. [1 ,2 ]
机构
[1] locat Acad Med Ctr, Dept Med Microbiol & Infect Prevent, Lab Expt Virol, Amsterdam UMC, Amsterdam, Netherlands
[2] Amsterdam Inst Immunol & Infect Dis, Amsterdam, Netherlands
[3] Publ Hlth Serv Amsterdam, Dept Infect Dis, Amsterdam, Netherlands
[4] Stichting HIV monitoring, Amsterdam, Netherlands
[5] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands
[6] Amsterdam UMC, Locat Acad Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands
[7] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY USA
关键词
VACCINE; OMICRON; IMMUNITY; SPIKE;
D O I
10.1371/journal.ppat.1012453
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by human sera is a strong correlate of protection against symptomatic and severe Coronavirus Disease 2019 (COVID-19). The emergence of antigenically distinct SARS-CoV-2 variants of concern (VOCs) and the relatively rapid waning of serum antibody titers, however, raises questions about the sustainability of serum protection. In addition to serum neutralization, other antibody functionalities and the memory B cell (MBC) response are suggested to help maintaining this protection. In this study, we investigate the breadth of spike (S) protein-specific serum antibodies that mediate effector functions by interacting with Fc-gamma receptor IIa (Fc gamma RIIa) and Fc gamma RIIIa, and of the receptor binding domain (RBD)-specific MBCs, following a primary SARS-CoV-2 infection with the D614G, Alpha, Beta, Gamma, Delta, Omicron BA.1 or BA.2 variant. Irrespectively of the variant causing the infection, the breadth of S protein-specific serum antibodies that interact with Fc gamma RIIa and Fc gamma RIIIa and the RBD-specific MBC responses exceeded the breadth of serum neutralization, although the Alpha-induced B cell response seemed more strain-specific. Between VOC groups, both quantitative and qualitative differences in the immune responses were observed, suggesting differences in immunogenicity. Overall, this study contributes to the understanding of protective humoral and B cell responses in the light of emerging antigenically distinct VOCs, and highlights the need to study the immune system beyond serum neutralization to gain a better understanding of the protection against emerging variants. The SARS-CoV-2 virus, first identified in 2019, swiftly led to a global pandemic. Crucial for the protection against re-infections are sufficient levels of neutralizing antibodies in the blood. However, SARS-CoV-2 have evolved into antigenically distinct variants of concern (VOC) that escape protection by these neutralizing antibodies. In addition, the relatively rapid waning of serum antibody titers raises questions about the sustainability of protection. In this study, we investigated the ability of antibodies and memory B cells to recognize the emerging variants after primary SARS-CoV-2 infection with different variants of concern. Compared with neutralizing antibodies, antibodies that can mediate Fc-mediated effector functions as well as memory B cells were, in general, more cross-reactive to other variants, irrespectively of the variant causing the infection. However, we found variations in the level of immune responses depending on the infecting variant, indicating differences in the immunogenicity of SARS-CoV-2 VOC. These results highlight the need to study the immune system beyond serum neutralization to gain a better understanding of the protection against emerging variants.
引用
收藏
页数:27
相关论文
共 35 条
  • [21] Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2
    Lazaro-Gorines, Rodrigo
    Perez, Patricia
    Heras-Murillo, Ignacio
    Adan-Barrientos, Irene
    Albericio, Guillermo
    Astorgano, David
    Flores, Sara
    Luczkowiak, Joanna
    Labiod, Nuria
    Harwood, Seandean L.
    Segura-Tudela, Alejandro
    Rubio-Perez, Laura
    Nugraha, Yudhi
    Shang, Xiaoran
    Li, Yuxing
    Alfonso, Carlos
    Adipietro, Kaylin A.
    Abeyawardhane, Dinendra L.
    Navarro, Rocio
    Compte, Marta
    Yu, Wenbo
    Mackerell, Alexander D.
    Sanz, Laura
    Weber, David J.
    Blanco, Francisco J.
    Esteban, Mariano
    Pozharski, Edwin
    Godoy-Ruiz, Raquel
    Munoz, Ines G.
    Delgado, Rafael
    Sancho, David
    Garcia-Arriaza, Juan
    Alvarez-Vallina, Luis
    ADVANCED SCIENCE, 2023, 10 (34)
  • [22] Patients with B-cell malignancies experience reduced antibody responses with class switching defect following BNT162b2 SARS-CoV-2 vaccination
    Nakagama, Yu
    Chi, Sung-Gi
    Minami, Yosuke
    Watanabe, Reiko
    Yamagishi, Michiteru
    Atsuko, Uno
    Kido, Yasutoshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2023, 29 (01) : 112 - 114
  • [23] Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
    Chang, Andres
    Lai, Lilin
    Akhtar, Akil
    Linderman, Susanne
    Orellana-Noia, Victor
    Saini, Manpreet
    Valanparambil, Rajesh
    Blum, Kristie
    Allen, Pamela
    Lechowicz, Mary
    Romancik, Jason
    Ayers, Amy
    O'Leary, Colin
    Churnetski, Michael
    Kives, Melissa
    Nooka, Ajay
    Koff, Jean
    Dhodapkar, Madhav
    Suthar, Mehul
    Cohen, Jonathon
    Ahmed, Rafi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S281 - S282
  • [24] SARS-CoV-2 epitope-specific CD4+ memory T cell responses across COVID-19 disease severity and antibody durability
    Nelson, Ryan W.
    Chen, Yuezhou
    Venezia, Olivia L.
    Majerus, Richard M.
    Shin, Daniel S.
    Carrington, Mary N.
    Yu, Xu G.
    Wesemann, Duane R.
    Moon, James J.
    Luster, Andrew D.
    SCIENCE IMMUNOLOGY, 2022, 7 (73)
  • [25] Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents
    Mu, Xiaofeng
    Cohen, Carolyn A.
    Leung, Daniel
    Duque, Jaime Rosa S.
    Cheng, Samuel M. S.
    Chung, Yuet
    Wong, Howard H. W.
    Lee, Amos M. T.
    Li, Wing Yan
    Tam, Issan Y. S.
    Lam, Jennifer H. Y.
    Lee, Derek H. L.
    Chan, Sau Man
    Tsang, Leo C. H.
    Chan, Karl C. K.
    Li, John K. C.
    Luk, Leo L. H.
    Chaothai, Sara
    Kwan, Kelvin K. H.
    Chu, Nym Coco
    Mori, Masashi
    Jeevan, Trushar
    Kandeil, Ahmed
    Webby, Richard J.
    Tu, Wenwei
    Valkenburg, Sophie A.
    Peiris, Malik
    Lau, Yu Lung
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [26] A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection
    Hassebroek, Anna M.
    Sooryanarain, Harini
    Heffron, Connie L.
    Hawks, Seth A.
    LeRoith, Tanya
    Cecere, Thomas E.
    Stone, William B.
    Walter, Debra
    Mahsoub, Hassan M.
    Wang, Bo
    Tian, Debin
    Ivester, Hannah M.
    Allen, Irving C.
    Auguste, Albert J.
    Duggal, Nisha K.
    Zhang, Chenming
    Meng, Xiang-Jin
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [27] Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+T cell responses
    Balachandran, Harikrishnan
    Phetsouphanh, Chansavath
    Agapiou, David
    Adhikari, Anurag
    Rodrigo, Chaturaka
    Hammoud, Mohamed
    Shrestha, Lok Bahadur
    Keoshkerian, Elizabeth
    Gupta, Money
    Turville, Stuart
    Christ, Daniel
    King, Cecile
    Sasson, Sarah C.
    Bartlett, Adam
    Grubor-Bauk, Branka
    Rawlinson, William
    Aggarwal, Anupriya
    Stella, Alberto Ospina
    Klemm, Vera
    Mina, Michael M.
    Post, Jeffrey J.
    Hudson, Bernard
    Gilroy, Nicky
    Konecny, Pam
    Ahlenstiel, Golo
    Dwyer, Dominic E.
    Sorrell, Tania C.
    Kelleher, Anthony
    Tedla, Nicodemus
    Lloyd, Andrew R.
    Martinello, Marianne
    Bull, Rowena A.
    CELL REPORTS, 2022, 38 (06):
  • [28] Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
    Ahmed-Belkacem, Abdelhakim
    Redjoul, Rabah
    Brillet, Rozenn
    Ahnou, Nazim
    Leclerc, Mathieu
    Lopez-Molina, Dennis Salomon
    Soulier, Alexandre
    Gourgeon, Aurelie
    Rodriguez, Christophe
    Maury, Sebastien
    Pawlotsky, Jean-Michel
    Fourati, Slim
    VIRUSES-BASEL, 2022, 14 (09):
  • [29] The role of antigen availability during B cell induction and its effect on sustained memory and antibody production after infection and vaccination-lessons learned from the SARS-CoV-2 pandemic
    Bjarnarson, Stefania P.
    Brynjolfsson, Siggeir F.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2022, 210 (03) : 273 - 282
  • [30] High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium
    Calcoen, Bas
    Callewaert, Nico
    Vandenbulcke, Aline
    Kerstens, Winnie
    Imbrechts, Maya
    Vercruysse, Thomas
    Dallmeier, Kai
    Van Weyenbergh, Johan
    Maes, Piet
    Bossuyt, Xavier
    Zapf, Dorinja
    Dieckmann, Kersten
    Callebaut, Kim
    Thibaut, Hendrik Jan
    Vanhoorelbeke, Karen
    De Meyer, Simon F.
    Maes, Wim
    Geukens, Nick
    VIRUSES-BASEL, 2022, 14 (06):